Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Retained Earnings: 2022-2025

Historic Retained Earnings for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$683.4 million.

  • Taysha Gene Therapies' Retained Earnings fell 17.13% to -$683.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$683.4 million, marking a year-over-year decrease of 17.13%. This contributed to the annual value of -$602.3 million for FY2024, which is 17.41% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Retained Earnings stood at -$683.4 million, which was down 5.03% from -$650.7 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Retained Earnings peaked at -$285.8 million during Q1 2022, and registered a low of -$683.4 million during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$560.7 million (2023), whereas its average is -$561.4 million.
  • Data for Taysha Gene Therapies' Retained Earnings shows a maximum YoY plummeted of 62.09% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Retained Earnings (Quarterly) stood at -$401.4 million in 2022, then dropped by 27.79% to -$513.0 million in 2023, then declined by 17.41% to -$602.3 million in 2024, then fell by 17.13% to -$683.4 million in 2025.
  • Its last three reported values are -$683.4 million in Q3 2025, -$650.7 million for Q2 2025, and -$623.8 million during Q1 2025.